tiprankstipranks
Love Pharma Inc (TSE:JOLT)
CNQX:JOLT

Love Pharma Inc (JOLT) Stock Price & Analysis

2 Followers

JOLT Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week Range<C$0.01 - C$0.03
Previous CloseC$0.01
Volume108.00
Average Volume (3M)N/A
Market Cap
C$386.45K
Enterprise ValueC$384.83K
Total Cash (Recent Filing)C$1.61K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)-0.8
Beta0.23
May 23, 2024
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding77,289,723
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.58
R-Squared0.00018
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

39.62%0.00%0.00%60.38%
39.62% Insiders
0.00% Other Institutional Investors
60.38% Public Companies and
Individual Investors

JOLT FAQ

What was Love Pharma Inc’s price range in the past 12 months?
Love Pharma Inc lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
    What is Love Pharma Inc’s market cap?
    Currently, no data Available
    When is Love Pharma Inc’s upcoming earnings report date?
    Love Pharma Inc’s upcoming earnings report date is May 23, 2024 which is in 13 days.
      How were Love Pharma Inc’s earnings last quarter?
      Currently, no data Available
      Is Love Pharma Inc overvalued?
      According to Wall Street analysts Love Pharma Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Love Pharma Inc pay dividends?
        Love Pharma Inc pays a Notavailable dividend of C$0.26 which represents an annual dividend yield of N/A. See more information on Love Pharma Inc dividends here
          What is Love Pharma Inc’s EPS estimate?
          Love Pharma Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Love Pharma Inc have?
          Love Pharma Inc has 77,289,730 shares outstanding.
            What happened to Love Pharma Inc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Love Pharma Inc?
            Currently, no hedge funds are holding shares in TSE:JOLT
            ---

            Love Pharma Inc Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Fundamentals

            Return on Equity
            -2515.27%
            Trailing 12-Months
            Asset Growth
            -54.65%
            Trailing 12-Months

            Company Description

            Love Pharma Inc

            Glenbriar Technologies Inc offers cloud-enabled business technology solutions in Canada. The company operates through the Information Technology segment. It provides business technology solutions in manufacturing, distribution, retail, energy, health, professional services, and real estate. The company also provides IT outsourcing and consulting services. It derives the majority of its revenue from Managed information services.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Aequus Pharmaceuticals
            Tetra Bio-Pharma
            Heritage Cannabis Holdings Corp
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis